Published in J Antimicrob Chemother on April 27, 2009
Recommended β-lactam regimens are inadequate in septic patients treated with continuous renal replacement therapy. Crit Care (2011) 1.91
Antibiotics in critically ill patients: a systematic review of the pharmacokinetics of β-lactams. Crit Care (2011) 1.48
Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections. Open Forum Infect Dis (2015) 1.34
Advances in the management of sepsis and the understanding of key immunologic defects. Anesthesiology (2011) 1.21
A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. Crit Care (2012) 1.18
ASAP ECMO: Antibiotic, Sedative and Analgesic Pharmacokinetics during Extracorporeal Membrane Oxygenation: a multi-centre study to optimise drug therapy during ECMO. BMC Anesthesiol (2012) 1.07
Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial. Crit Care (2012) 1.05
Does Beta-lactam Pharmacokinetic Variability in Critically Ill Patients Justify Therapeutic Drug Monitoring? A Systematic Review. Ann Intensive Care (2012) 0.99
Importance of relating efficacy measures to unbound drug concentrations for anti-infective agents. Clin Microbiol Rev (2013) 0.99
The Japanese guidelines for the management of sepsis. J Intensive Care (2014) 0.99
Polymyxin B in Combination with Antimicrobials Lacking In Vitro Activity versus Polymyxin B in Monotherapy in Critically Ill Patients with Acinetobacter baumannii or Pseudomonas aeruginosa Infections. Antimicrob Agents Chemother (2015) 0.97
Antibiotic dosing in the 'at risk' critically ill patient: Linking pathophysiology with pharmacokinetics/pharmacodynamics in sepsis and trauma patients. BMC Anesthesiol (2011) 0.97
Impact of Bolus dosing versus continuous infusion of Piperacillin and Tazobactam on the development of antimicrobial resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother (2013) 0.96
The prevention and management of infections due to multidrug resistant organisms in haematology patients. Br J Clin Pharmacol (2015) 0.92
The combined effects of extracorporeal membrane oxygenation and renal replacement therapy on meropenem pharmacokinetics: a matched cohort study. Crit Care (2014) 0.91
Dosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe gram-negative infections: a pharmacokinetics/pharmacodynamics-based approach. Antimicrob Agents Chemother (2012) 0.90
Assessment of pharmacokinetic changes of meropenem during therapy in septic critically ill patients. BMC Pharmacol Toxicol (2014) 0.90
Comparing the Outcomes of Patients With Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Bacteremia. Clin Infect Dis (2016) 0.90
The ECMO PK Project: an incremental research approach to advance understanding of the pharmacokinetic alterations and improve patient outcomes during extracorporeal membrane oxygenation. BMC Anesthesiol (2013) 0.88
Ertapenem-Containing Double-Carbapenem Therapy for Treatment of Infections Caused by Carbapenem-Resistant Klebsiella pneumoniae. Antimicrob Agents Chemother (2015) 0.86
Continuous beta-lactam infusion in critically ill patients: the clinical evidence. Ann Intensive Care (2012) 0.85
The pharmacokinetics of cefazolin in patients undergoing elective & semi-elective abdominal aortic aneurysm open repair surgery. BMC Anesthesiol (2011) 0.85
DALI: Defining Antibiotic Levels in Intensive care unit patients: a multi-centre point of prevalence study to determine whether contemporary antibiotic dosing for critically ill patients is therapeutic. BMC Infect Dis (2012) 0.85
Beta-lactam dosing in critically ill patients with septic shock and continuous renal replacement therapy. Crit Care (2014) 0.84
Optimal dosing of antibiotics in critically ill patients by using continuous/extended infusions: a systematic review and meta-analysis. Crit Care (2013) 0.83
Continuous infusion of antibiotics in the critically ill: The new holy grail for beta-lactams and vancomycin? Ann Intensive Care (2012) 0.82
How to treat VAP due to MDR pathogens in ICU patients. BMC Infect Dis (2014) 0.81
Cerebrospinal fluid penetration of meropenem in neurocritical care patients with proven or suspected ventriculitis: a prospective observational study. Crit Care (2016) 0.81
Ceftazidime dosage regimen in intensive care unit patients: from a population pharmacokinetic approach to clinical practice via Monte Carlo simulations. Br J Clin Pharmacol (2012) 0.80
Population Pharmacokinetics of Fosfomycin in Critically Ill Patients. Antimicrob Agents Chemother (2015) 0.78
Pharmacodynamic Evaluation of the Potential Clinical Utility of Fosfomycin and Meropenem in Combination Therapy against KPC-2-Producing Klebsiella pneumoniae. Antimicrob Agents Chemother (2016) 0.78
A 30-years review on pharmacokinetics of antibiotics: is the right time for pharmacogenetics? Curr Drug Metab (2014) 0.78
Comparison of the accuracy and precision of pharmacokinetic equations to predict free meropenem concentrations in critically ill patients. Antimicrob Agents Chemother (2014) 0.78
Carbapenem-Resistant Enterobacteriaceae Infections in Children. Curr Infect Dis Rep (2016) 0.77
Population Pharmacokinetics and Target Attainment of Meropenem in Plasma and Tissue of Morbidly Obese Patients after Laparoscopic Intraperitoneal Surgery. Antimicrob Agents Chemother (2015) 0.77
Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients. Eur J Clin Pharmacol (2016) 0.77
Population pharmacokinetics of meropenem in elderly patients: dosing simulations based on renal function. Eur J Clin Pharmacol (2016) 0.76
A Simulation Study Reveals Lack of Pharmacokinetic/Pharmacodynamic Target Attainment in De-escalated Antibiotic Therapy in Critically Ill Patients. Antimicrob Agents Chemother (2015) 0.76
Meropenem therapy in extracorporeal membrane oxygenation patients: an ongoing pharmacokinetic challenge. Crit Care (2015) 0.76
In Vivo Microdialysis To Determine Subcutaneous Interstitial Fluid Penetration and Pharmacokinetics of Fluconazole in Intensive Care Unit Patients with Sepsis. Antimicrob Agents Chemother (2015) 0.76
Substantial Impact of Altered Pharmacokinetics in Critically Ill Patients on the Antibacterial Effects of Meropenem Evaluated via the Dynamic Hollow-Fiber Infection Model. Antimicrob Agents Chemother (2017) 0.75
Continuous infusion of meropenem in critically ill patients: practical considerations. Crit Care (2012) 0.75
Meropenem dosing requirements against Enterobacteriaceae in critically ill patients: influence of renal function, geographical area and presence of extended-spectrum β-lactamases. Eur J Clin Microbiol Infect Dis (2016) 0.75
Hydroxyethyl starch or saline for fluid resuscitation in intensive care. N Engl J Med (2012) 11.83
International study of the prevalence and outcomes of infection in intensive care units. JAMA (2009) 11.57
Augmented renal clearance in the ICU: results of a multicenter observational study of renal function in critically ill patients with normal plasma creatinine concentrations*. Crit Care Med (2014) 5.50
DALI: defining antibiotic levels in intensive care unit patients: are current β-lactam antibiotic doses sufficient for critically ill patients? Clin Infect Dis (2014) 3.99
Vancomycin-associated nephrotoxicity in the critically ill: a retrospective multivariate regression analysis*. Crit Care Med (2014) 3.45
A multicenter randomized trial of atorvastatin therapy in intensive care patients with severe sepsis. Am J Respir Crit Care Med (2013) 3.44
Adult-population incidence of severe sepsis in Australian and New Zealand intensive care units. Intensive Care Med (2004) 3.30
Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med (2009) 3.09
A new marker of sepsis post burn injury?*. Crit Care Med (2014) 3.05
Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clin Infect Dis (2012) 2.88
Continuation of statin therapy in patients with presumed infection: a randomized controlled trial. Am J Respir Crit Care Med (2010) 2.21
A systematic review on clinical benefits of continuous administration of beta-lactam antibiotics. Crit Care Med (2009) 2.17
Diagnostic accuracy of cystatin C compared to serum creatinine for the estimation of renal dysfunction in adults and children--a meta-analysis. Clin Biochem (2007) 2.06
Variability of antibiotic concentrations in critically ill patients receiving continuous renal replacement therapy: a multicentre pharmacokinetic study. Crit Care Med (2012) 2.04
Grey goo on the skin? Nanotechnology, cosmetic and sunscreen safety. Crit Rev Toxicol (2007) 1.95
A comparison of epinephrine and norepinephrine in critically ill patients. Intensive Care Med (2008) 1.87
Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia. Blood (2013) 1.87
Management of meningitis due to antibiotic-resistant Acinetobacter species. Lancet Infect Dis (2009) 1.87
The impact of hospital and ICU organizational factors on outcome in critically ill patients: results from the Extended Prevalence of Infection in Intensive Care study. Crit Care Med (2015) 1.85
Increased mortality associated with methicillin-resistant Staphylococcus aureus (MRSA) infection in the intensive care unit: results from the EPIC II study. Int J Antimicrob Agents (2011) 1.80
Continuous infusion of beta-lactam antibiotics in severe infections: a review of its role. Int J Antimicrob Agents (2007) 1.76
Interventions that can reduce inappropriate prescribing in the elderly: a systematic review. Drugs Aging (2009) 1.76
Dry-coated microprojection array patches for targeted delivery of immunotherapeutics to the skin. J Control Release (2009) 1.71
Antibiotic resistance--what's dosing got to do with it? Crit Care Med (2008) 1.67
Intercontinental dispersal of bacteria and archaea by transpacific winds. Appl Environ Microbiol (2012) 1.65
Optimal doripenem dosing simulations in critically ill nosocomial pneumonia patients with obesity, augmented renal clearance, and decreased bacterial susceptibility. Crit Care Med (2013) 1.63
First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int J Antimicrob Agents (2009) 1.52
The impact of variation in renal replacement therapy settings on piperacillin, meropenem, and vancomycin drug clearance in the critically ill: an analysis of published literature and dosing regimens*. Crit Care Med (2014) 1.51
Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin Pharmacokinet (2010) 1.49
Characteristics and determinants of outcome of hospital-acquired bloodstream infections in intensive care units: the EUROBACT International Cohort Study. Intensive Care Med (2012) 1.47
A comparison of estimates of glomerular filtration in critically ill patients with augmented renal clearance. Crit Care (2011) 1.47
Free tropospheric transport of microorganisms from Asia to North America. Microb Ecol (2012) 1.46
Severity Scores in Emergency Department Patients With Presumed Infection: A Prospective Validation Study. Crit Care Med (2016) 1.45
Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin Pharmacokinet (2006) 1.43
Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. Int J Antimicrob Agents (2010) 1.43
Continuous measurement of cerebral blood flow velocity using transcranial Doppler reveals significant moment-to-moment variability of data in healthy volunteers and in patients with subarachnoid hemorrhage. Crit Care Med (2002) 1.39
The effects of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients. Clin Pharmacokinet (2011) 1.39
Quantifying pain relief following administration of a novel formulation of paracetamol (acetaminophen). J Clin Pharmacol (2010) 1.38
Nanoparticles and microparticles for skin drug delivery. Adv Drug Deliv Rev (2011) 1.36
Rapid and simple high-performance liquid chromatographic assay for the determination of metformin in human plasma and breast milk. J Chromatogr B Analyt Technol Biomed Life Sci (2002) 1.36
Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units. J Antimicrob Chemother (2006) 1.36
Toward improved surveillance: the impact of ventilator-associated complications on length of stay and antibiotic use in patients in intensive care units. Clin Infect Dis (2012) 1.33
A preliminary study of atorvastatin plasma concentrations in critically ill patients with sepsis. Intensive Care Med (2008) 1.33
Population pharmacokinetics and pharmacodynamics of ofloxacin in South African patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother (2012) 1.33
Medication reviews in the community: results of a randomized, controlled effectiveness trial. Br J Clin Pharmacol (2004) 1.31
Human skin penetration of sunscreen nanoparticles: in-vitro assessment of a novel micronized zinc oxide formulation. Skin Pharmacol Physiol (2007) 1.31
Antioxidative function of L-FABP in L-FABP stably transfected Chang liver cells. Hepatology (2005) 1.29
Augmented creatinine clearance in traumatic brain injury. Anesth Analg (2010) 1.28
Potent immunity to low doses of influenza vaccine by probabilistic guided micro-targeted skin delivery in a mouse model. PLoS One (2010) 1.27
Patient barriers to and enablers of deprescribing: a systematic review. Drugs Aging (2013) 1.27
Influence of elevated CO(2) on the fungal community in a coastal scrub oak forest soil investigated with terminal-restriction fragment length polymorphism analysis. Appl Environ Microbiol (2002) 1.26
Development and validation of a novel molecular biomarker diagnostic test for the early detection of sepsis. Crit Care (2011) 1.26
The influence of the Pharmaceutical Benefits Scheme (PBS) on inappropriate prescribing in Australian nursing homes. Pharm World Sci (2007) 1.24
The use of prophylactic fluconazole in immunocompetent high-risk surgical patients: a meta-analysis. Crit Care (2005) 1.24
Principles of antibacterial dosing in continuous renal replacement therapy. Crit Care Med (2009) 1.23
The relationship between drug clearance and body size: systematic review and meta-analysis of the literature published from 2000 to 2007. Clin Pharmacokinet (2012) 1.22
Protein binding of β-lactam antibiotics in critically ill patients: can we successfully predict unbound concentrations? Antimicrob Agents Chemother (2013) 1.21
Vancomycin dosing in critically ill patients: robust methods for improved continuous-infusion regimens. Antimicrob Agents Chemother (2011) 1.21
Analysis of population pharmacokinetic data using NONMEM and WinBUGS. J Biopharm Stat (2005) 1.18
Better outcomes through continuous infusion of time-dependent antibiotics to critically ill patients? Curr Opin Crit Care (2008) 1.17
Implications of augmented renal clearance in critically ill patients. Nat Rev Nephrol (2011) 1.17
Piperacillin penetration into tissue of critically ill patients with sepsis--bolus versus continuous administration? Crit Care Med (2009) 1.16
Nanopatch-targeted skin vaccination against West Nile Virus and Chikungunya virus in mice. Small (2010) 1.16
Vancomycin pharmacokinetics in critically ill patients receiving continuous venovenous haemodiafiltration. Br J Clin Pharmacol (2004) 1.16
Clinical implications of antibiotic pharmacokinetic principles in the critically ill. Intensive Care Med (2013) 1.15
Does severe non-infectious SIRS differ from severe sepsis? Results from a multi-centre Australian and New Zealand intensive care unit study. Intensive Care Med (2008) 1.14
Therapeutic drug monitoring of beta-lactams for critically ill patients: unwarranted or essential? Int J Antimicrob Agents (2010) 1.14
Imaging of zinc oxide nanoparticle penetration in human skin in vitro and in vivo. J Biomed Opt (2009) 1.13
People's attitudes, beliefs, and experiences regarding polypharmacy and willingness to Deprescribe. J Am Geriatr Soc (2013) 1.13
Physiologically based synthetic models of hepatic disposition. J Pharmacokinet Pharmacodyn (2006) 1.13
Cardiac troponin may be released by ischemia alone, without necrosis. Clin Chim Acta (2009) 1.11
Principles and clinical application of assessing alterations in renal elimination pathways. Clin Pharmacokinet (2003) 1.10
Monte Carlo simulations: maximizing antibiotic pharmacokinetic data to optimize clinical practice for critically ill patients. J Antimicrob Chemother (2010) 1.10
Plasma and tissue pharmacokinetics of cefazolin in patients undergoing elective and semielective abdominal aortic aneurysm open repair surgery. Antimicrob Agents Chemother (2011) 1.09
A standard weight descriptor for dose adjustment in the obese patient. Clin Pharmacokinet (2004) 1.08
Molecular size as the main determinant of solute maximum flux across the skin. J Invest Dermatol (2004) 1.08
Increased fluid resuscitation can lead to adverse outcomes in major-burn injured patients, but low mortality is achievable. Burns (2008) 1.05
Returning to the pre-antibiotic era in the critically ill: the XDR problem. Crit Care Med (2007) 1.05
Lean body mass normalizes the effect of obesity on renal function. Br J Clin Pharmacol (2008) 1.05
Antimicrobial pharmacokinetic and pharmacodynamic issues in the critically ill with severe sepsis and septic shock. Crit Care Clin (2011) 1.04
Augmented renal clearance in the Intensive Care Unit: an illustrative case series. Int J Antimicrob Agents (2010) 1.04
Using PK/PD to optimize antibiotic dosing for critically ill patients. Curr Pharm Biotechnol (2011) 1.04
Review of deprescribing processes and development of an evidence-based, patient-centred deprescribing process. Br J Clin Pharmacol (2014) 1.03